Combination of organic compounds useful for treating diabetes
View Patent ↗The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) an AT 1 -receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
1. A pharmaceutical composition, wherein the active ingredients consist of
(i) valsartan or a pharmaceutically acceptable salt thereof;
(ii) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof selected from the group consisting of a DPP-IV inhibitor, GLP1 or GLP1 agonist; and
(iii) a pharmaceutically acceptable carrier.
2. A composition according to claim 1 wherein the insulin secretion enhancer is the DPP-IV inhibitor pyrrolidine 1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-,(S) or a pharmaceutically acceptable salt thereof.
3. A method for treating diabetes comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 .